Skip to content
ClinCalc Pro
Menu
paediatrics

Withdrawal Assessment Tool (WAT-1) for Paediatric Iatrogenic Withdrawal

Validated 11-item tool for assessing iatrogenic opioid and benzodiazepine withdrawal in critically ill children. Assesses symptoms over the past 12 hours plus a 2-minute observation period.

Score interpretation

No Significant Withdrawal 0–2

WAT-1 < 3 -- no significant iatrogenic withdrawal detected

→ Continue current weaning plan; WAT-1 assessment every 4-8 hours during opioid/benzo wean; document score; reassess if clinical concern changes; if on opioid wean: typically reduce by 10-20% per day if WAT-1 < 3 consistently; continue non-pharmacological comfort measures: swaddling, positioning, skin-to-skin, minimal stimulation, cluster care.

Significant Withdrawal -- Manage Opioid/Benzo Wean 3–12

WAT-1 >= 3 -- significant iatrogenic withdrawal; treatment modification required

→ Pause or slow opioid/benzo wean; consider rescue dose: 10% of total daily opioid equivalent as PRN dose; if WAT-1 consistently >= 3 on current wean rate: increase total daily dose by 10-20% then restart slower wean; pharmacological adjuncts for withdrawal: clonidine 1-5 mcg/kg/dose 4-6 hourly (reduces noradrenergic symptoms, allows faster wean); methadone transition if prolonged IV opioid use (> 5-7 days): methadone 0.05-0.1 mg/kg/dose BD-TDS; assess and manage autonomic symptoms: HR, BP, temperature; GI symptoms: loperamide not recommended in children; minimise stimulation (low light, noise reduction, cluster care); family support and explanation; PICU/paediatric pharmacist review of weaning protocol; document WAT-1 frequency and scores.

Interpretation bands for the WAT-1. Apply clinical judgement and local guidance.

References

Related

Curated clinical cross-links plus same-class fallbacks.

Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.